Current and emerging strategies for treating hepatic encephalopathy

Crit Care Nurs Clin North Am. 2010 Sep;22(3):341-50. doi: 10.1016/j.ccell.2010.04.007.

Abstract

Hepatic encephalopathy (HE) is caused by liver impairment and has a multitude of symptoms in affected patients, including change in level of consciousness, intellectual function, and neuromuscular function. Pharmacologic therapy includes use of nonabsorbable disaccharides (lactulose and lactitol), and antibiotics such as neomycin, paromycin, metronidazole, and rifaximin. Probiotics, acarbose, and drugs such as L-carnitine and flumazenil, may also be helpful in treating HE.

Publication types

  • Review

MeSH terms

  • Acarbose / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Carnitine / administration & dosage
  • Dyskinesias / etiology
  • Electroencephalography
  • Flumazenil / therapeutic use
  • GABA Modulators / therapeutic use
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Hemorrhage / complications
  • Hepatic Encephalopathy / classification
  • Hepatic Encephalopathy / complications
  • Hepatic Encephalopathy / diagnosis
  • Hepatic Encephalopathy / epidemiology
  • Hepatic Encephalopathy / therapy*
  • Humans
  • Hyperammonemia / drug therapy
  • Lactulose / administration & dosage
  • Lactulose / therapeutic use
  • Probiotics / administration & dosage
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • GABA Modulators
  • Gastrointestinal Agents
  • Flumazenil
  • Lactulose
  • Carnitine
  • Acarbose